Item 8.01 Other Events On July 30, 2024, the Company issued a press release regarding its Phase 2 TAMARACK clinical trial of vobramitamab duocarmazine in metastatic castration-resistant prostate cancer (the “ Press Release”). The full text of the Press Release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit Number Description of Exhibit 99.1 Press Release dated July 3 0, 2024 ────────────────────────────────────────────────────────────────────────────────────────────── 104 Cover Page Interactive Data (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 30, 2024 MACROGENICS, INC. ───────────────────────────────────────────────────────────────────────────────────────────── By: /s/ Jeffrey Peters